| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 5174 | 2014 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020-1030, 2014 | 2785 | 2014 |
| Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma HA Tawbi, D Schadendorf, EJ Lipson, PA Ascierto, L Matamala, ... New England Journal of Medicine 386 (1), 24-34, 2022 | 1466 | 2022 |
| PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ... New England Journal of Medicine 374 (26), 2542-2552, 2016 | 1383 | 2016 |
| Evolutionary dynamics of cancer in response to targeted combination therapy I Bozic, JG Reiter, B Allen, T Antal, K Chatterjee, P Shah, YS Moon, ... elife 2, e00747, 2013 | 723 | 2013 |
| Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma EJ Lipson, CG Drake Clinical cancer research 17 (22), 6958-6962, 2011 | 700 | 2011 |
| Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ... Clinical Cancer Research 19 (2), 462-468, 2013 | 677 | 2013 |
| Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors FB Cortazar, KA Marrone, ML Troxell, KM Ralto, MP Hoenig, JR Brahmer, ... Kidney international 90 (3), 638-647, 2016 | 653 | 2016 |
| Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy L Heinzerling, PA Ott, FS Hodi, AN Husain, A Tajmir-Riahi, H Tawbi, ... Journal for immunotherapy of cancer 4, 1-11, 2016 | 555 | 2016 |
| Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer CG Drake, EJ Lipson, JR Brahmer Nature reviews Clinical oncology 11 (1), 24-37, 2014 | 549 | 2014 |
| PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival EJ Lipson, JG Vincent, M Loyo, LT Kagohara, BS Luber, H Wang, H Xu, ... Cancer immunology research 1 (1), 54-63, 2013 | 455 | 2013 |
| Cardiovascular toxicities associated with immune checkpoint inhibitors JR Hu, R Florido, EJ Lipson, J Naidoo, R Ardehali, CG Tocchetti, AR Lyon, ... Cardiovascular research 115 (5), 854-868, 2019 | 441 | 2019 |
| Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy P Nghiem, S Bhatia, EJ Lipson, WH Sharfman, RR Kudchadkar, AS Brohl, ... Journal of Clinical Oncology 37 (9), 693-702, 2019 | 412 | 2019 |
| Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab LC Cappelli, AK Gutierrez, AN Baer, J Albayda, RL Manno, U Haque, ... Annals of the rheumatic diseases 76 (1), 43-50, 2017 | 405 | 2017 |
| Antagonists of PD-1 and PD-L1 in cancer treatment EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian Seminars in oncology 42 (4), 587-600, 2015 | 346 | 2015 |
| Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma L Chen, J Douglass, L Kleinberg, X Ye, AE Marciscano, PM Forde, ... International Journal of Radiation Oncology* Biology* Physics 100 (4), 916-925, 2018 | 329 | 2018 |
| Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1 … PA Ascierto, I Melero, S Bhatia, P Bono, RE Sanborn, EJ Lipson, ... Journal of Clinical Oncology 35 (15_suppl), 9520-9520, 2017 | 280 | 2017 |
| Tumor regression and allograft rejection after administration of anti–PD-1 EJ Lipson, SM Bagnasco, J Moore Jr, S Jang, MJ Patel, AA Zachary, ... New England Journal of Medicine 374 (9), 896-898, 2016 | 276 | 2016 |
| Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer TJ Williams, DR Benavides, KA Patrice, JO Dalmau, ALR De Ávila, DT Le, ... JAMA neurology 73 (8), 928-933, 2016 | 275 | 2016 |
| Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma SY Cho, EJ Lipson, HJ Im, SP Rowe, EM Gonzalez, A Blackford, ... Journal of Nuclear Medicine 58 (9), 1421-1428, 2017 | 258 | 2017 |
janis taubeProfessor of Dermatology, Pathology, and Oncology, Johns Hopkins University SOMכתובת אימייל מאומתת בדומיין jhmi.edu
